Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer

Aggregation Tests Identify New Gene Associations With Breast Cancer in Populations With Diverse Ancestry

A Model for Predicting Both Breast Cancer Risk and Non-Breast Cancer Death Among Women Older Than 55 Years Old

GRHL2-Controlled Gene Expression Networks in Luminal Breast Cancer

Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

High Deductibles Lead Women to Skip Testing After Abnormal Mammogram

Aggrego Pulse - 1/19/23

Breast Cancer Patients From the Midwest Region of the United States Have Reduced Levels of Short-Chain Fatty Acid-Producing Gut Bacteria

Trastuzumab Deruxtecan Improves Survival vs Standard of Care for HER2-Low Metastatic Breast Cancer

header-info

Sep, 19, 2022

Debra Patt, MD, PhD, MBA, Texas Oncology, US Oncology Network, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with HER2-low metastatic breast cancer.